CLL & Mantle Cell Lymphoma: Immediate Impact of 2014 ASCO Presentations on Clinical Practice

Introduction

In an effort to provide you with timely market feedback from ASCO 2014, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ from the meeting. This second report explored presentations in Chronic lymphocytic leukemia (CLL) and other B cell lymphomas.

OncoPoll™ Methodology

  • Primary research phase involved a global survey to verified and validated oncologists and multi-disciplinary physicians with an identified clinical interest in CLL and other B cell lymphomas utilizing targeting parameters within the proprietary MDoutlook® global cancer treater database
  • Timing: June 2014. Launched three days after close of 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL., May 30-June 3, 2014
  • Fielding via <10 minute long interactive internet survey utilizing proven effective methodology via the MDoutlook survey tool
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Reponses at data collection: 49 on June 24th
  • No financial incentives provided for participation

Geographic Distribution of Respondents

Attendance at 2014 ASCO Annual Meeting

Key Conclusions

  • Less than 50% of survey respondents attended this year’s ASCO annual meeting
  • Fewer proportion of attendees than in previous years (typically has been a 50/50 split); also lower than for two other ASCO2014 OncoPolls. This reflects higher percentage of hematologic oncologists as survey respondents who more typically attend ASH and EHA instead of ASCO

P

Survey Participants’ CLL and Other B Cell Lymphoma Patient Flow:  Averaged at Least 16 CLL Cases Each Quarter

Key Conclusions

  • Survey participants* averaged 30 cases of CLL (treatment naïve) in last 3 months
    • Nearly double CLL (relapsed/refractory) or DLBCL patients
  • Survey participants* also averaged 19 mantle cell patients in the last 3 months

* Survey Participants = Oncologists with an identified clinical interest in CLL and other B cell lymphomas

P

Usage of Ibrutinib for CLL Patients: Impact of the RESONATE Trial

Key Conclusions

  • In the next three months, 43% of Del 17p patients and 32% of Del 11q patients are expected to be treated with ibrutinib
  • In comparison to ibrutinib usage for CLL patients in the last three months, the usage of ibrutinib in the next three months for treatment naïve patients is expected to increase by 189%
  • Usage of ibrutinib for relapsed/refractory, Del 17p, and Del 11q patients is expected to increase by ~100% (relative percent increase between 106%-116%)

P

Oral Syk Inhibitor for Relapsed/Refractory CLL: Impact of GS-9973

Key Conclusions

  • Oncologists recognize that there will be a clinical impact due to GS-9973
  • Nearly 40% of oncologists believe that GS-9973 will have a large impact on a minority of relapsed/refractory CLL patients
    • 30% believe that GS-9973 will only have a small impact on a minority of relapsed/refractory CLL patient
  • Only a small percentage (11-15%) of oncologists believe that GS-9973 will have an impact of any size on a majority of these patients

P

Impact of VR-CAP in the Front-Line Setting for Mantel Cell Lymphoma

Key Conclusions

  • A slightly higher proportion of Oncologists would chose to use VR-CAP (42%) for their transplant-ineligible Mantle cell lymphoma patients, in comparison to using R-CHOP (36%)
  • 21% of oncologists would prefer to use other regimens as a front line treatment

P

Conclusions: Impact of ASCO 2014 on Clinical Practices for CLL and Mantle Cell Lymphoma

  • CLL-treatment naïve is the largest proportion of lymphoma patients seen in clinical practices
    • Mantle cell lymphoma patients are the second most seen per quarter
  • In comparison to ibrutinib usage for CLL patients in the last three months, the usage of ibrutinib in the next three months for treatment naïve patients is expected to increase by ~200%
    • Usage of ibrutinib for relapsed/refractory, Del 17p, and Del 11q patients is expected to increase by ~100%
  • The highest proportion of oncologists (39%) believe that GS-9973 will have a large impact to a minority of their relapsed/refractory CLL patients
    • A small percentage (11-15%) of oncologists believe that GS-9973 will have an impact of any size on a majority of their of relapsed/refractory CLL patients
  • Oncologists would expect to use VR-CAP in a higher proportion (42%) of their transplant-ineligible Mantle cell lymphoma patients in comparison to R-CHOP (36%)

P

For a more detailed analysis report, please click here to download the full report.

Submitted by Robert Stephan, Sr. Director Medical Services and Strategy; Jessica Harnisch, Assoc. Global Medical Analyst; and Jan Heybroek, President MDoutlook.

article register

Recent Posts

Recent Comments

Archives

Categories

  1. Stephanie, thank you for your insightful comment. You were correct and we have re-analyzed the data to find there was an inconsistency. The graphs and conclusions related to ibrutinib have been updated in this blog. You can download the full report on our website, link provided in the blog. Thanks!

  2. One of the key conclusions stated in this blog is “In the next three months, 37.9% of Del 17p patients and 28.4% of Del 11q patients are expected to be treated with Ibrutinib”, but this is not what the data graph appears to show. The data graph seems to be reporting the distribution of all ibrutinib use across various patient segments (that’s why it totals 100%). So shouldn’t the conclusion be “of all ibrutinib use, 37.9% will be in Del 17p patients and 28.4% will be in Del 11q patients.” I would have liked to see the total % of these patient segments who will receive ibrutinib (vs. other options), but from the data shown above it does not appear this can be calculated.

Post a Comment

Your email is never shared. Required fields are marked *